An experimental Alzheimer’s drug therapy has slowed cognitive and functional decline by 27% versus placebo in a double-blind, randomized study of 1,795 individuals with early signs and symptoms of the disease.

Patients with autoimmune hepatitis may be better monitored across disease stages by AI-augmented multiparametric MRI than by liver biopsy, as the imaging has proven less costly and is inherently less risky due to its noninvasiveness. 

With 91% sensitivity but only 25% specificity, the tool is worthwhile for clinicians who remain wary of frequent false positives that would send patients with no fractures for unneeded imaging.

A pharmaceutical compound approved 21 years ago to treat breast cancer in postmenopausal women is showing fresh promise as a therapy for glioblastomas. 

The boon comes in the form of greater brain cortical thickness observable on neonatal MRI two weeks after the baby enters the world.

The FDA has given its thumbs-up to software that calculates breast fibroglandular tissue volume (FGV) and the ratio of FGV to total breast volume on ultrasound imaging.

Researchers in the U.K. have documented fetuses smiling when exposed to sweet flavors and frowning over bitter tastes.

A machine learning system has come along that needs no human labeling of data for training yet matches radiologists at classifying diseases on chest X-rays—including some that the model was not specifically taught to detect.